Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: BioRad, Nanosphere

Premium

BioRad Laboratories stockholders have re-elected Louis Drapeau and Albert Hillman as class A directors, and Deborah Neff, Alice Schwartz, and Norman Schwartz as class B directors.


Nanosphere announced the appointment of Ken Bahk as its chief strategy officer, a new position, and that CTO Tim Patno and board member Chad Mirkin will be leaving the company.

Bahk was part of Nanosphere's initial team, and served with the company until 2008. In his new role at Nanosphere, he will be responsible for driving strategic plans and revenues in molecular diagnostics.

He is currently a director of investments at Lurie Investments and previously served as the chair of strategic opportunities for the Association for Molecular Pathology.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.